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Abstract
Studies of haploidentical hematopoietic stem cell transplantation (HSCT) have identified
threshold doses of T cells below which severe graft-versus-host (GVHD) is usually absent.
However, little is known regarding optimal T cell dosing as it relates to engraftment, immune
reconstitution, and relapse. To begin to address this question, we developed a 2 step
myeloablative approach to haploidentical HSCT in which 27 patients conditioned with total body
irradiation (TBI) were given a fixed dose of donor T cells (HSCT step 1), followed by
cyclophosphamide (CY) for T cell tolerization. A CD34 selected HSC product (HSCT step 2)
was infused after CY. A dose of 2 x108/kg T cells resulted in consistent engraftment, immune
reconstitution, and acceptable rates of GVHD. Cumulative incidences of grade III-IV GVHD,
non-relapse mortality and relapse-related mortality were 7.4%, 22.2%, and 29.6% respectively.
With a follow-up of 28-56 months, 3 year probability of overall survival for the whole cohort is
48% and 75% in patients without disease at HSCT. In the context of CY tolerization, a high,
fixed dose of haploidentical T cells was associated with encouraging outcomes especially in
good risk patients, and can serve as the basis for further exploration and optimization of this 2
step approach.

Presented in part in abstract form at the 51st annual meeting of the American Society of
Hematology, New Orleans, La.

ClinicalTrials.gov Identifier NCT00429143

Page |3

GROSSO et al.

T CELL OPTIMIZATION IN HAPLO-HSCT

Introduction
Until recently, HLA haploidentical HSCT has often been associated with disappointing clinical
outcomes limiting the widespread application of this approach. Higher rates of infection and
relapse, two consequences of the T cell depletion required to prevent severe GVHD in
recipients of HLA mismatched grafts, adversely impact long term survival particularly in patients
transplanted late in their disease course. Because only a subset of appropriate transplant
candidates has an HLA identical sibling or unrelated donor, the development of safer, more
efficacious transplant approaches using haploidentical donors would provide potential transplant
options for patients who lack well-matched donors.

Based on murine models, clinical approaches to haploidentical transplantation initially relied on
aggressive T cell depletion techniques. Ex-vivo T cell depletion with soy bean agglutinin and E
rosetting or the use of monoclonal antibodies such as T10B9 resulted in marrow products
containing T cell doses in the range of 104 to 105 T cells/kg of recipient body weight. This
degree of T cell depletion was associated with the attenuation of severe GVHD and provided
consistent

engraftment,

particularly

when

anti-thymocyte

globulin

(ATG)

was

also

administered.1,2 The correlate of a high degree of T cell depletion to avoid GVHD is delayed
post-transplant immune recovery,3-9 mortality from infection and relapse,1,10-16 and higher rates
of graft rejection as compared to T cell-containing regimens.17 Ruggeri and colleagues18
demonstrated that the higher relapse rates associated with T cell depletion can be moderated in
part by maximizing natural killer (NK) cell alloreactivity.

However, infectious mortality still

remains an obstacle to long term survival even with this approach.

Much of the data regarding the permissible content of T cells in the donor innocula was
necessarily based on the correlation between T cell doses and the development of GVHD as
opposed to immune reconstitution. Severe GVHD was infrequent to absent with T cell doses of
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less than 1x 105/kg in adults undergoing matched sibling HSCT

19

and with less than 5 x 104/kg

in children undergoing haploidentical HSCT.20 Huang et al.21 reported encouraging rates of
disease-free survival but a cumulative incidence of chronic GVHD that exceeded 50% when a
median T cell dose of 2.4 x 108/kg was administered with ATG to recipients of haploidentical
HSCT utilizing combined blood and marrow products from recombinant human granulocyte
colony-stimulating factor (G-CSF) primed donors.

The use of T cell add-back,22 selective lymphocyte depletion of donor grafts,23,24 and preemptive
DLI 25, 26 are strategies used after T cell depleted haploidentical HSCT to preserve or restore the
beneficial immune reconstituting effects of T cells. Another approach involves the use of posttransplant CY after non-myeloablative marrow grafts from haploidentical donors to preferentially
delete activated lymphocytes as opposed to a non-selective depletion of all CD 3+ T cells.

27-29

In one report,28 there were low infectious rates and little significant GVHD associated with the
infusion of donor products containing a mean number of 4.2 x 107/kg T cells. Despite the use
of these relatively high T cell-containing products, the rejection rate of 13% was higher, and the
disease free survival rate was lower, than that reported by Huang et al.21 possibly due to the
administration of comparatively less T cells, the use of a non-myeloablative conditioning
regimen, or a combination of the two.

These trials demonstrate that outcomes after haploidentical HSCT can be influenced by the
dosing, timing, and treatment of donor T cells. Potential barriers to further progress include the
lack of consistency in T cell dosing from which to compare and optimize outcomes and
methodologies to deliver consistent T cell doses at the time of HSCT. An ideal approach would
maximize the number of “safe”, non-alloreactive T cells, avoiding the problems of GVHD while
preserving the beneficial effects of T cells with regard to engraftment, infectious complications,
and relapse. Moreover, while murine models of transplantation virtually always administer a
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fixed dose of T cells to produce more consistent immunologic outcomes, human HSCT grafts
contain a more highly variable number of passenger lymphocytes.

We therefore developed a 2 step myeloablative approach to haploidentical HSCT in which our
primary goal was to provide a fixed, and ideally maximized, dose of T cells in the context of CY
tolerization. Myeloablative rather than reduced intensity conditioning was used to provide more
treatment intensity to high-risk patients. In the setting of myeloablative conditioning, we wished
to maximize the number of T cells which could be safely administered and to use the higher
number of stem cells which can be obtained from peripheral blood rather than marrow to avoid
rejection.

Because there was no data regarding T cell dosing with CY tolerization in a

myeloablative setting, the trial was designed as a phase I/II study in which an optimal dose of T
cells would be initially determined, based on the incidences of graft rejection and of GVHD. The
goal of the phase II part of the study was to assess whether this optimized dose of
cyclophosphamide-tolerized T cells would result in rapid immune constitution and low rates of
severe infection, rejection, relapse, and significant GVHD, thus resulting in improved overall
survival.

Methods
The 2 step transplant regimen
Patients received 12 Gy of TBI administered in 8 fractions over 4 days on days -9 to -6. After
the last fraction of TBI, a DLI product was administered to deliver a specific dose of donor CD3+
T cells (see below) representing step one (the lymphoid portion) of the transplant. Days -5 and 4 were rest days. CY 60 mg/kg/day was given on days -3 and -2. Tacrolimus and
Mycophenolate Mofetil were initiated on day-1 for GVHD prophylaxis. A CD 34 selected donor
stem cell product was infused on day 0, representing step two (the stem cell portion) of the
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transplant. Granulocyte-macrophage colony stimulating factor (GM-CSF) 250µg/m2 was begun
on day +1. No steroids were permissible until after the second dose of CY. In the absence of
GVHD, Mycophenolate Mofetil was discontinued on day 28 after HSCT and a tacrolimus taper
was initiated by day +60.

Study design and endpoints
The primary endpoint of the phase I part of the study was to determine the optimal (or maximum
feasible) dose of CD3+ T cells that could be given with CY tolerization that would result in
reliable engraftment without significant GVHD. After review of T cell numbers in allogeneic
peripheral stem cell products at our institution, we hypothesized that 2 x 108 CD3+ cells/kg
would produce consistent engraftment and started the trial at that dose. The study design was
such that the dose of T cells would be escalated if excessive graft failure was observed or
decreased if excessive GVHD was observed. If excessive graft failure and GVHD were both
observed at the same T cell dose, the study would close. The study was also designed to close
if, after 4 dose adjustments (up or down) an appropriate T cell dose could not be identified.
Once a dose was identified where 6 patients achieved successful engraftment without
significant (grade III/IV) GVHD, the phase I part of this protocol would close, and subsequent
patients would be treated at this dose in the phase II portion of the trial.

Since our goal was to develop a regimen that allowed haploidentical HSCT to be performed with
low treatment related mortality (TRM) and since we anticipated a high relapse rate in the high
risk patients likely to enter such a trial, the primary endpoint of the phase II part of the trial was
demonstrate an overall survival of ≥ of 30% at 6 months. Secondary endpoints included the
assessment of engraftment rates, immune reconstitution and infection, and incidence and
severity of GVHD.
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Recipient consent, eligibility, donor selection
Written informed consent was obtained for all of the patients in accordance with the Declaration
of Helsinki. The study was approved by the Institutional Review Board of Thomas Jefferson
University. Patients were eligible for inclusion if they had received front-line therapy for their
disease, were without an available genotypically identical related donor, had an available
related donor that was mismatched for > 2 HLA antigens (HLA-A, B, C, DRB1) in the GVH
direction, had adequate organ function as defined by a serum creatinine of ≤ 2.0 mg/dl or
creatinine clearance of > 40 ml/min, pulmonary diffusion capacity > 45% (corrected for
hemoglobin), and cardiac ejection fraction > 45%, had a Karnofsky Performance Status > 70%,
were HIV negative, were not pregnant, and had no other active malignancies. Donors were
selected to try to maximize anti-host alloreactivity based on factors such as a higher degree of
HLA mismatch or the presence of KIR mismatches.

Collection of cells, graft characteristics and processing
Donors underwent apheresis on days -7 and -6 to collect the DLI product. The desired dose of
CD 3+ cells was infused without manipulation after the last fraction of TBI on D-6.

After

collection of the DLI product, donors received subcutaneous injections of G-CSF, 5 µg/kg BID
on days -5 through -1, and underwent apheresis for hematopoietic stem cells (HSC) on days -2
and -1. The HSC product underwent CD 34 selection using the Isolex 300i magnetic cell
selection system (Baxter) followed by treatment with muromonab-CD3 (OKT-3 Ortho-Biotech) to
decrease residual T cell amounts after selection.

The product was washed after OKT-3

incubation prior to infusion to ensure that any infused OKT-3 was cell bound and that free OKT3 was not administered. Processing and infusion of the HSC product occurred on day 0.
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Definitions
White cell engraftment was defined as an absolute neutrophil count (ANC) of > 0.5x109/L for at
least 3 consecutive days post-transplant. Platelet engraftment was defined as a platelet count of
> 20,000/µl without transfusion for the 7 preceding days. Toxicities were graded using National
Cancer Institute (NCI) criteria (Common Toxicity Criteria). Acute GVHD was scored based on
the Glucksberg system.30 Grades III-IV GVHD was termed “severe” GVHD. Chronic GVHD was
based on the National Institutes of Health Consensus Criteria.31

Post-transplant supportive care
Patients were monitored weekly with a quantitative CMV PCR assay performed on blood
samples. If the test became positive, patients were pre-emptively treated with foscarnet or
valganciclovir. Patients were given intravenous gamma globulin therapy every 3 to 4 weeks until
IgG levels returned to the normal range.

Statistical analysis
The phase I portion of the trial was based on a continual reassessment method and the final T
cell dose was determined based on the observed clinical outcomes as described above. Six
month survival was estimated using the Kaplan-Meier method (SPSS software, version 12).
Cumulative incidence of grades II-IV GVHD, grades III-IV GVHD, engraftment, and relapse were
all calculated with death as a competing risk using R v 2.11.1.

Results
Patients
A total of 27 patients, median age of 52 years (range 19-67) with high risk hematologic
malignancies were treated between the years of 2006 and 2009. Patient, donor, and disease
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characteristics are listed in Table 1. Patients and donors were mismatched for 2 (n = 2), 3
(n=11), or 4 (n=13) HLA-A, B, C, or DR antigens in the GVHD direction. A single patient with
zero mismatches in the GVH direction and 4 mismatches in the host-versus-graft (HVG)
direction because of HLA homozygosity was treated on the trial.

T cell dose (transplant step 1) and subsequent in vivo alloreaction
The initial T cell dose in this trial was 2 x 108 CD 3+ cells/kg. This dose resulted in consistent
engraftment and acceptable rates of severe GVHD. Consequently, no dose escalation or deescalation was performed and all study patients received this dose except for one patient whose
donor product contained only 1.7 x 108 T cells despite two days of apheresis. This patient
engrafted and did not develop significant GVHD.

Unexpectedly, patients developed fever (median temperature 103.8◦F) within 24 hours of the
DLI. Virtually all patients developed diarrhea coincident with or shortly after onset of the fever.
Approximately 25% of patients developed rash in the same time frame. Two of the patients who
developed a rash and diarrhea in this time frame underwent biopsies which showed
histopathologic evidence of GVHD. Fever and diarrhea were resistant to antipyretics and other
supportive measures. However, in all cases, these symptoms abated after the second dose of
CY. A typical fever curve is shown in Figure 1.

CD34 dose (transplant step 2) and engraftment
CD34 and residual CD3 content of the second step of the graft is summarized in Table 2. Two
patients died before engraftment could be evaluated. One patient with a flare of Crohn’s
disease the week prior to HSCT (GVH direction mismatches = 0) developed hypotension and
adult respiratory distress syndrome shortly after transplant. He died on day +9 from a
presumed bowel event related to his Crohn’s disease. A second patient died of respiratory
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syncytial virus pneumonitis (GVH direction mismatches = 3) on day +1. These two patients were
evaluated for toxicity only.

Twenty-three of the remaining 25 patients had full donor engraftment. Neutrophil recovery
occurred at a median of 12 days (range = 9-15) and platelet recovery occurred at a median of
20.5 days (range = 15-46). Cumulative incidence of engraftment for neutrophils and platelets
was 85.2% and 74.1% respectively (Figure 2). Two multiparous females with multiple HLA
antibodies rejected grafts from their daughters. The first patient had an HLA class I anti-donor
antibody and was successfully engrafted using a reduced intensity conditioning regimen and an
alternate haploidentical donor. The second patient demonstrated an HLA class II anti-donor
antibody. This patient, who had no suitable alternate donor, was given 4 doses of Rituximab and
apheresis followed by a reduced intensity conditioning regimen and was successfully engrafted
using the original donor. Both patients who rejected their transplants had markedly different
temperature curves as compared to those who successfully engrafted, with an earlier
appearance of the initial temperature rise but a far milder fever later in the course. Their fever
curves were more typical during their second transplants. The fever curves of these patients
are shown in Figure 1.

TRM
There were three deaths due to multi-organ failure. These included the patient with a flare of
Crohn’s disease described above. The other 2 deaths occurred in the patients who experienced
primary graft failure. Although these patients were subsequently successfully engrafted, both
died of multi-organ failure presumably due to the combined toxicities of the conditioning
regimens used for two transplants in rapid succession.

P a g e | 11

GROSSO et al.

T CELL OPTIMIZATION IN HAPLO-HSCT

Infection and immune reconstitution
Three of 27 patients (11%) died of infection (bacterial sepsis with subsequent brain abscess-1,
progression of pre-existing fungal pneumonia-1, RSV pneumonia-1) during the transplant
admission.

Sixteen patients alive and without evidence of recurrent disease at 6 months post HSCT were
analyzed with regard to their immune reconstitution. Their median CD3+/CD4+ cell count at day
+28 was 33.6 cells/µl (range 11.5-171.8), rising to a median of 104.6 cells/µl (range 10-403.27)
at day +100. The median CD3+/CD8+ cell count at day +28 was 28.7 cells/µl (range 3.83160.09), rising to 151.3 cells/µl (range 2.31-2379.8) at day 100. Lower CD3+/CD4+ and
CD3+/CD8+ counts were associated with the use of corticosteroids for GVHD. The CD3+/CD4+
and CD3+/CD8+ counts for these patients are shown in Figure 3. Patients treated earlier in the
trial who developed GVHD were treated more aggressively and appeared to have slower CD4
count recovery. There was no consistent pattern to CD4/CD8 ratios, although several patients
developed very elevated CD3+/CD8+ counts at the time of infections.

No patient died of complications related to CMV reactivation, although the majority of patients
who were CMV seropositive developed evidence of reactivation (15 of 18) whether their donor
was CMV seropositive or not. There were no cases of CMV tissue infection.

GVHD
None of the 25 evaluable patients died from GVHD. Only 2 of 25 (8%) patients developed
severe acute GVHD. One patient developed steroid responsive grade III intestinal GVHD and
one patient, having previously developed stage III skin GVHD which resolved with steroids and
photopheresis, later developed grade IV liver GVHD which responded to treatment with OKT-3.
Fourteen others developed grade II skin GVHD, with the majority of these patients (11) having
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stage III skin disease only without evidence of GVHD in the liver or GI tract. Their skin GVHD
responded to steroids (n=8) or steroids plus photopheresis (n =3). Three patients had grade I
GVHD responding primarily to topical steroids. Four of 25 evaluable patients (16%) developed
chronic GVHD, score 1. Cumulative incidences of grades II-IV and grades III-IV GVHD were
59.2% and 7.4%, respectively (Figure 4).

Cumulative incidence of non-relapse mortality (NRM) at the time of the most recent follow-up
was 22.2% (Figure 5).

Relapse and overall survival
Relapsed disease was the primary cause of death in patients treated on this trial. Eight of 25
patients (32%) experienced a relapse of their malignancies 49-327 days post HSCT. Cumulative
incidence of death due to relapse (RRM) was 29.6% (Figure 5). Six of 13 patients with active
malignancy at the time of HSCT subsequently relapsed, while only two of 12 patients who
underwent transplant while in remission relapsed afterwards. All patients who relapsed
ultimately died from their malignancy, and all patients who are alive are at least 28 months post
HSCT without evidence of their disease.

Seventeen of 27 patients (63%) were alive 6 months after their transplant, satisfying the primary
endpoint of the trial. Kaplan-Meier estimate of overall survival was 54% at 1 year and 48 % at 3
years (median follow up 40 months, range 28-56 months). Patients without disease at the time
of HSCT fared better with a projected OS of 75% at 3 years. Survival curves are shown in
Figure 6. All surviving patients remain in CR and have been followed for a minimum of 24
months post-transplant.
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Discussion
Our goals in developing this 2 step regimen were: to develop a myeloablative regimen for
haploidentical HSCT that could be administered to patients with refractory or relapsed
hematological malignancies initially, but would subsequently be appropriate for high risk
patients earlier in their disease course who lacked other donor options; to avoid exposure of
newly transplanted HSCs to high dose CY; to utilize peripheral blood rather than marrow as the
stem cell source; and to fix and maximize the number of CD3 cells patients would receive in an
effort to produce consistent outcomes following transplantation. Of these, we considered the
standardization of the CD3 dose to be the most essential. Every animal transplant model
carefully controls and fixes CD3 content, yet this is rarely done in clinical transplantation with the
exception of trials of T cell depletion where the focus is often on a T cell threshold rather than a
dose. Essentially we believed that controlling the T cell dose was equally important to the
outcome of transplant as prescribing specific doses of radiation and chemotherapy.

The initially tested T cell dose of 2 x 108/kg was associated with prompt engraftment, little
significant GVHD, and prompt immunological recovery and thus met our phase I criteria for an
optimal dose of T cells within the context of these immunologic outcome measures. In contrast
to our own experience with T depleted haploidentical HSCT, deaths from infection at this T cell
dose were very low despite a high rate of CMV reactivation. In many patients, the reactivation
was accompanied by a rise in CD3+/CD4+ and CD3+/CD8+ T cells, although the circulating T
cells were not tested for CMV specificity. In our prior experience with global T cell depletion,
patients remained severely T lymphopenic throughout the course of viral infections. With CY
tolerization, CMV reactivation was typically rapidly controlled once immune suppression was
tapered. Twenty-one of twenty-seven patients (78%) survived until discharge and all
subsequent deaths were related solely to relapsed disease and not TRM.
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We did not anticipate the two rejections in patients with donor specific antibodies (DSA)
especially in the context of a large T cell dose and the successful engraftment of a patient
treated earlier in the trial with very broadly reactive anti-HLA antibodies, but who was without
DSA. It is possible that the atypical early fevers in these two patients were a reflection of an
antibody mediated lysis of the donor lymphocytes shortly after infusion which allowed residual
host humoral and cellular immunity to reject the graft. Rejection resulting from DSA was not
well described at the time this trial was launched and a retrospective review of the literature
revealed only one trial that described this phenomenon.32 Few additional reports have been
published since this time and the cumulative experience, including our own, suggests that the
presence of DSA is a significant risk factor for rejection of haploidentical grafts. 33,34 In the
absence of DSA, over 60 patients treated with this 2 step approach either within this particular
trial or subsequent to it have engrafted, demonstrating that without anti-donor antibodies,
engraftment is consistent.

The incidence of GVHD was higher in this trial versus that reported in other haploidentical trials
where CY tolerization was used as GVHD prophylaxis.28 This likely reflects the 5 fold higher T
cell dose that was administered, the aggressive taper of immune suppression, efforts to select
the donor predicted to be most alloreactive amongst the available family members and the
more intensive conditioning regimen. Nonetheless, GVHD was primarily limited to skin and
easily controlled with steroids or steroids and early photopheresis. Photopheresis is thought to
ameliorate GVHD in part by increasing CD4+CD25+/FoxP3+ T regulatory cells (Tregs).35,36 The
role of Tregs in controlling haploidentical GVHD after using this 2 step HSCT approach is an
area of current inquiry.
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Chronic GVHD was infrequent and was not severe. This positive outcome likely contributed to
the absence of late non-relapse mortality as most patients did not require chronic immune
suppression.

The febrile reaction, rash and diarrhea that resulted from the T cell infusion are reminiscent of
the “haplo immunostorm” (HIS) described by Colvin and colleagues 37 when they infused similar
doses of T cells following 2 Gy of radiation without other cytoreduction. In that setting, HIS was
thought to be mediated by a cytokine storm and not associated with GVHD or engraftment
syndrome. In our 2 step approach, the reaction resolved completely after two doses of CY and
morphological analysis of skin and gut biopsies were consistent with GVHD. In the Colvin et al.
study, this phenomenon was observed when the CD3 dose reached 1 x 108/kg and was most
pronounced at 2 x 108/kg, the dose utilized in this trial. Similar febrile reactions were not
reported by O’Donnell 29 and colleagues, probably because their median T cell dose was 5 fold
lower than in our trial.

We believe that during this in vivo alloreaction, donor lymphocytes contribute to the
immunologic elimination of residual malignancy. This is supported by the Colvin group’s
observation that patients receiving haploidentical cellular therapy for resistant malignancy had
clinical responses at the doses of T cells associated with HIS despite the minimal conditioning
administered.

One of the rationales for the two step approach described here was that donor lymphocytes
would be exposed to CY while hematopoietic stem and progenitor cells would not. While stem
cells may be protected from mutagenic effects of CY due to their expression of aldehyde
dehydrogenase, levels of this enzyme drop as cells diverge from the stem cell phenotype.
Some current models of leukemogenesis posit that mutations occur in a post stem precursor
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cell which, as a consequence, reacquires stem properties. Whether secondary MDS or AML
will emerge as problems in regimens where HSCs are exposed to CY remains to be seen. The
two step approach eliminates that issue, however big or small it may be. It does require 4 days
of apheresis for most donors (2 for DLI and 2 for HSC), but this has been well tolerated to date.

The 52% and 48% one and three year overall survival rates observed in patients treated on this
two-step regimen met the protocol criteria for an effective regimen. Based on the current
literature, the results appear comparable to outcomes in matched sibling and unrelated donor
HSCT in similar high risk groups of patients. All six patients treated for lymphoid diseases, four
patients with high-risk ALL and two patients with chemotherapy-resistant non-Hodgkin
lymphoma, are disease-free 28 to 52 months post-transplant. Whether these favorable
outcomes were due to the use of TBI in the conditioning regimen or to the large number of
haploidentical T cells administered with this approach is unknown. If the latter is true, it may
alter the spectrum of diseases in which strong graft-versus-tumor (GVT) effects are observed
after haploidentical transplantation.

Administration of the graft in two steps avoided the infusion of donor T cells that were skewed
towards a TH2 phenotype since T cells were collected prior to administering G-CSF to the
donors. Recognizing the high risk nature of the patients treated, we also administered GM-CSF
rather than G-CSF after transplant in a further attempt to avoid G-CSF-induced polarization to a
TH2 phenotype.38 Despite this strategy, relapsed disease in patients with AML or MDS was the
primary cause of mortality. Interestingly, six of the eight (75%) recipients that relapsed,
including the only two patients who relapsed following transplantation while in remission, were
mothers receiving grafts from their children. Recent data supports a mechanism of long-lasting
regulatory T cell mediated tolerance of maternal cells by offspring.39 While child to mother
transplants have been associated with superior outcomes in other transplant settings,40 in our
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limited population they were associated with higher rates of relapse. It is possible that the
outcomes associated with this donor-recipient combination are dependent on the particular
disease state and transplant regimen which together will determine whether an increase or
decrease in alloreactivity is likely to be beneficial or detrimental.

Building on the platform of a large and consistent T cell dose, additional strategies can be
explored with the potential to improve relapse rates in patients with advanced malignancies.
Mayumi and Good demonstrated in murine models that the administration of CY 1-3 days after
antigenic stimulation is the optimal time to establish allogeneic tolerance. 41 The optimal timing
in man has not been directly studied. It may be worthwhile to assess whether the interval
between DLI and CY can be safely increased modestly in future trials as a means of allowing
further immunologically mediated cytoreduction by the DLI prior to abrogation by CY. Other
drugs preferentially cytoxic to activated cells such as Melphalan 42,43 could potentially be
introduced in place of CY using this 2 step approach without concerns about cytotoxicity toward
hematopoietic stem cells. This platform also allows the use of two haploidentical donors to
further increase the GVT effect and eliminate the potential for leukemic escape due to
uniparental disomy.44

The results from this trial have been encouraging amongst patients undergoing transplant in
remission with a follow up of in excess of two years for all patients. The low regimen related
mortality and high overall survival suggests that this approach can be extended to better risk
patients earlier in their disease course and should be further studied in larger trials.
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Table 1. Patient Characteristics
Number of Subjects
Median Age, years (range)
Sex (M/F)
Race

27
Recipient
Donor
52 (19-67)
39 (24-65)
11/16
White
19

Black
6

Disease and Disease Status at HSCT
AML CR1 with High Risk Features*
AML CR2
AML Primary Induction Failure
AML in Resistant Relapse
Biphenotypic Leukemia with Disease at HSCT
ALL CR2 (Ph-)
ALL (Ph+) Morphologic Remission
MDS
NHL Chemotherapy Resistant
Aplastic Anemia

5
2
2
7
1
3
1
2
3
1

Previous Transplant
Secondary Malignancy

2
2

Recipient/Donor Transplant Combinations
Sibling to Sibling / Parent to Child / Child to
Parent

Asian
2

7 / 4 / 16

CMV Serostatus Recipient (R) and Donor (D)
R+/D+
R+/DR-/D-

12
6
9

# HLA Antigen Mismatches (GVH Direction)
(A, B, Cw, DRB1)
Four
Three
Two
Zero†

13
11
2
1

KIR Mismatches††
KIR ligand missing in recipient but present in
donor
HLA-C Group 1
5
HLA-C Group 2
4
HLA- Bw4
1
HLA-C and HLA Bw4
2
No KIR Mismatch
15
* Based on cytogenetics, secondary disease, CNS/tissue involvement, or arising from MDS
†
Patient had 4 mismatches in HVG direction only and was counted for toxicity only
††
Missing self as defined by Ruggeri et al.18
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Figure 1. Fever Curves after DLI Correlate with Clinical Events. A
typical temperature curve from an engrafting patient is shown in green. Curves
from the two patients with anti-donor antibodies who rejected their grafts are
shown in red and blue. The boundary between the febrile and afebrile ranges
(100.4 °F) is shown by the horizontal solid black line. The afebrile range is
shaded gray. Engrafting patients generally developed within 24 hours after DLI.
The fever spikes persisted despite the use of acetaminophen and other comfort
measures until after the second dose of CY. In the setting of anti-donor
antibodies, the patients developed fever within a few hours of the DLI, rapidly
defervesced and remained afebrile thereafter.
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Table 2. Graft Characteristics
Step 1

Step 2

CD3+/kg x108

CD34+/kg x106

Median (Range)

Median (Range)

2.0 (1.7 in 1 patient,
2.0 in 26 patients)
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3.6

(1.3-7.4)

Residual CD3+ Cells/kg
in CD 34+ Product x104
Median (Range)
0.51

(0.13-6.9)
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Engraftment
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Cumulative Incidence

0.8

Platelets ≥20,000
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Figure 2. Neutrophil and Platelet Engraftment. Cumulative incidences of
neutrophil and platelet engraftment were 85.2% and 74.1% respectively.
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Figure 3.

Immune Recovery after Haploidentical Transplant.

CD3+/CD4+ cell counts (A) and CD3+/CD8+ cell counts (B) of 16 patients alive
and disease-free at least 6 months post HSCT are illustrated.
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Figure 4. Acute GVHD. Cumulative incidences of grades II-IV and III-IV GVHD
were 59.2 % and 7.4% respectively.
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Figure 5. Relapse and Non-Relapse Related Mortality. Cumulative
incidences of RRM and NRM were 29.6% and 22.2% respectively.
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Figure 6. Probability of Overall Survival. Survival for all
patients in the trial is shown as the solid black line (48% 3
year OS). Patients without marrow morphologic or
radiographic evidence of disease at the time of transplant are
shown with the dashed line (75% 3 year OS). Patients with
marrow or radiographic evidence of disease are shown in the
dotted line (27% 3 year OS).
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